Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Study 329 was a clinical trial which was conducted in North America from 1994 to 1998 to study the efficacy of paroxetine, an SSRI anti-depressant, in treating 12- to 18-year-olds diagnosed with major depressive disorder. Led by Martin Keller, then professor of psychiatry at Brown University, and funded by the British pharmaceutical company SmithKline…
Art, Standards & Companies
Explore the main themes, entities and connections around Study 329. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
paroxetine gsk study placebo 329 efficacy article data mhra drug smithkline clinical beecham depression safety jaacap trial children imipramine trials
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Study 329 | Call for retraction | May 2003, April 2013 | 1.00 | infobox |
| Study 329 | Dates | 1994–1998 | 1.00 | infobox |
| Study 329 | Disputed article | Martin B. Keller, et al. (July 2001). "Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial", Journal of the American Academy o… | 1.00 | infobox |
| Study 329 | Funding | SmithKline Beecham, now GlaxoSmithKline (GSK) | 1.00 | infobox |
| Study 329 | Lead researcher | Martin Keller, then professor of psychiatry, Brown University | 1.00 | infobox |
| Study 329 | Legal penalty | GSK fined in 2012 by US Department of Justice | 1.00 | infobox |
| Study 329 | Locations | 10 centres in the United States, two in Canada | 1.00 | infobox |
| Study 329 | Protocol | "Study drug: BRL29060/Paroxetine (Paxil)", SmithKline Beecham, 20 August 1993, amended 24 March 1994. | 1.00 | infobox |
| Study 329 | Published | July 2001 | 1.00 | infobox |
| Study 329 | Retracted | No | 1.00 | infobox |
| Study 329 | Study reanalysis | Joanna Le Noury, et al. (16 September 2015). "Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence", BMJ, 351, 16… | 1.00 | infobox |
| Study 329 | Study type | Eight-week, placebo-controlled, double-blind, randomized clinical trial comparing paroxetine with imipramine in adolescents with major depressive disorder | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.